T. Mantilla

发表

Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease.

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2017 .

Consecución de objetivos terapéuticos

T. Mantilla, 2014 .

Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2019, Clínica e Investigación en Arteriosclerosis (English Edition).

Factors associated with the discontinuation of evidence-based cardiovascular therapies in patients with stable coronary artery disease: a primary care perspective

J. Mostaza, C. Lahoz, T. Mantilla, 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

Consensus document on the management of the atherogenic dyslipidaemia of the Spanish Society of Arteriosclerosis.

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2017, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Consensus document on the management of the atherogenic dyslipidaemia of the Spanish Society of Arteriosclerosis.

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2017 .

Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease.

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2017, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Gender differences in evidence-based pharmacological therapy for patients with stable coronary heart disease.

C. Lahoz, T. Mantilla, S. Tranche, 2009, International journal of cardiology.

Fibrates in primary prevention of cardiovascular disease. Comments on the results of a systematic review of the Cochrane Collaboration

A. Hernández-Mijares, Á. Brea, X. Pintó, 2018, Clínica e Investigación en Arteriosclerosis (English Edition).

Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (I). Nonalcoholic fatty liver disease and its association with cardiovascular disease.

J. Pedro-Botet, Á. Brea, X. Pintó, 2017, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Evidence-based cardiovascular therapies and achievement of therapeutic goals in diabetic patients with coronary heart disease attended in primary care.

C. Lahoz, T. Mantilla, S. Tranche, 2006, American heart journal.

[PREVENCAT study: control of cardiovascular risk in primary care].

J. Banegas, L. Ruilope, V. Barrios, 2005, Medicina clinica.

Variables associated with change in blood pressure control status after 1-year follow up in primary care: a retrospective analysis: the TAPAS study

C. Escobar, M. Leal, C. Suarez, 2014, European journal of preventive cardiology.

Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects.

A. Hernández-Mijares, Á. Brea, X. Pintó, 2018, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (i). Nonalcoholic fatty liver disease and its association with cardiovascular disease

Á. Brea, X. Pintó, P. González-Sántos, 2017 .

[Tables of coronary risk evaluation adapted to the Spanish population: the DORICA study].

S. Monereo, L. Serra Majem, J. Aranceta, 2004, Medicina clinica.

Fibrates in the secondary prevention of cardiovascular disease (infarction and stroke). Results of a systematic review and meta-analysis of the Cochrane collaboration

A. Hernández-Mijares, Á. Brea, X. Pintó, 2018 .

The gap between dyslipidemia control perceived by physicians and objective control patterns in Spain.

J. Banegas, F. Civeira, T. Mantilla, 2006, Atherosclerosis.

Non-HDL cholesterol as a therapeutic goal.

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2019, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (I). Nonalcoholic fatty liver disease and its association with cardiovascular disease.

J. Pedro-Botet, Á. Brea, Á. Brea, 2017, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects.

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2019, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Fibrates in primary prevention of cardiovascular disease. Comments on the results of a systematic review of the Cochrane Collaboration.

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2018, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.